Camlin Fine Sciences Q1FY27 Revenue Up 27.5% YoY to ₹5,199 Million
Camlin Fine Sciences reported Q1FY27 consolidated revenue of ₹5,199 million, up 27.5% YoY. EBITDA stood at ₹176 million. Specialty Ingredients revenue grew 41% YoY, Blends by 35%, and Aroma by 37%. The company faces challenges from higher raw material and logistics costs but expects continued growth.
The revenue growth is positive, but the decrease in EBITDA margin and the recognition of an exceptional item due to an insurance claim shortfall indicate some financial pressures that temper the overall impact.
The company reported a significant year-on-year revenue growth of 27.5%, driven by strong performance across its key segments, indicating positive business momentum despite operational challenges.
Camlin Fine Sciences Limited announced its investor presentation for the quarter ended June 30, 2026 (Q1FY27). The company reported a consolidated revenue of ₹5,199 million, marking a significant year-on-year increase of 27.5%.
Despite a challenging operating environment characterized by higher raw material and logistics costs, leading to a 159 basis point negative impact on EBITDA, the company managed its operating expenses effectively. The Gross Margin stood at 41.2%, a decrease from 48.5% in Q4 FY26, attributed to higher raw material prices and limited pass-through. The EBITDA for the quarter was ₹176 million, with a margin of 3.4%. An exceptional item of ₹111 million was recognized due to a shortfall in the settlement of an insurance claim for the fire at its Brazil unit.
Segmental highlights show strong performance across various verticals. Specialty Ingredients (Straights) revenue grew by 41% YoY to ₹927 million. Blends revenue increased by 35% YoY, with Vinpai contributing ₹247 million. The Aroma segment saw revenue grow by 37% YoY, driven by steady realisations and volumes of Vanillin. The company aims for Aroma to breakeven in the coming quarters, with improving growth trajectories for Vanillin.
Looking ahead to FY27, the company anticipates continued growth momentum in its Blends segment across geographies, with Vitafor and Vinpai expected to stabilize. The Aroma segment is projected to improve its growth trajectory with steady realisations. However, the lingering conflict situation may pose near-term challenges related to transit times, operating cycles, and inflationary pressures. The company is focusing on improving margins, optimizing its working capital cycle, and developing new products in functional ingredients.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.